Skip to main content

Advertisement

Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia

Fig. 3

a OS in 41 AML patients with complete consolidation therapy classify by cytogenetic risk. b OS in 41 AML patients with complete consolidation therapy with HiDAC and IDAC regimen. c RFS in 41 AML patients with complete consolidation therapy classify by cytogenetic risk. d RFS in 41 AML patients with complete consolidation therapy with HiDAC and IDAC regimen

Back to article page